A Multicenter, Open-label Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)

Registry ID

EUCTR2014-001449-26

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Seikagaku Corporation

Start date

2015-03-02

Completion date

2017-03-17

Last update

2026-08-16

Conditions

• Lumbar disc herniation

Summary

The primary study objective is to evaluate the safety of a single dose intervertebral disc injection of SI-6603 at a dose of 1.25 U in patients with lumbar disc herniation, for a 26 week follow-up period.

Locations

• , , Spain
• , , Germany

View on source registry